What COMPUGEN LTD's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 1 | 12 |
| Total trades | 11 | 37 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 37 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Halevy Gilead | Director | Jul 29 | Grant / award · A | +7,500 | — | — | 18,907 |
| Livnat Savitzky Kinneret | Director | Jul 29 | Grant / award · A | +7,500 | — | — | 20,850 |
| Levine Zurit | SVP, Business Development | Jul 29 | Grant / award · A | +18,000 | — | — | 47,375 |
| Zweifach Sanford S | Director | Jul 29 | Grant / award · A | +7,500 | — | — | 20,180 |
| Mahler Michelle | Chief Medical Officer | Jul 29 | Grant / award · A | +13,500 | — | — | 36,625 |
| Hukkelhoven Mathias | Director | Jul 29 | Grant / award · A | +7,500 | — | — | 17,500 |
| Kredo Russo Sharon | SVP, Research & Discovery | Jul 29 | Grant / award · A | +18,000 | — | — | 37,500 |
| Perry Eran | Director | Jul 29 | Grant / award · A | +7,500 | — | — | 17,500 |
| Silberman David | Chief Financial Officer | Jul 29 | Grant / award · A | +19,500 | — | — | 55,000 |
| Levine Zurit | SVP, Business Development | Jul 09 | Open-market sale · S | −1,875 | $2.50 | −$4.69K | 29,375 |
| Levine Zurit | SVP, Business Development | Jul 09 | Exercise / conversion · M | +1,875 | $0.83 | +$1.55K | 31,250 |
| Ophir Eran | President and CEO | Apr 24 | Open-market sale · S | −5,000 | $3.20 | −$16K | 11,375 |
| Ophir Eran | President and CEO | Apr 24 | Exercise / conversion · M | +5,000 | $0.83 | +$4.15K | 16,375 |
| Levine Zurit | SVP, Business Development | Apr 24 | Open-market sale · S | −2,000 | $3.20 | −$6.4K | 29,375 |
| Levine Zurit | SVP, Business Development | Apr 24 | Exercise / conversion · M | +2,000 | $1.15 | +$2.3K | 31,375 |
| Levine Zurit | SVP, Business Development | Apr 14 | Open-market sale · S | −2,000 | $2.80 | −$5.6K | 29,375 |
| Levine Zurit | SVP, Business Development | Apr 14 | Exercise / conversion · M | +2,000 | $1.15 | +$2.3K | 31,375 |
| Ophir Eran | President and CEO | Apr 14 | Open-market sale · S | −5,000 | $2.90 | −$14.5K | 11,375 |
| Ophir Eran | President and CEO | Apr 14 | Exercise / conversion · M | +5,000 | $0.83 | +$4.15K | 16,375 |
| Levine Zurit | SVP, Business Development | Apr 10 | Open-market sale · S | −3,125 | $2.56 | −$8.01K | 29,375 |
Loading...